Cargando…

Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes

OBJECTIVE: Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE. METHODS: We conducted a PK analysis using data from two observational pregnancy registries. We enrolled pregnant women with SLE ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Balevic, Stephen J, Weiner, Daniel, Clowse, Megan E B, Eudy, Amanda M, Maharaj, Anil R, Hornik, Christoph P, Cohen-Wolkowiez, Michael, Gonzalez, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744126/
https://www.ncbi.nlm.nih.gov/pubmed/34996856
http://dx.doi.org/10.1136/lupus-2021-000602
_version_ 1784630054538444800
author Balevic, Stephen J
Weiner, Daniel
Clowse, Megan E B
Eudy, Amanda M
Maharaj, Anil R
Hornik, Christoph P
Cohen-Wolkowiez, Michael
Gonzalez, Daniel
author_facet Balevic, Stephen J
Weiner, Daniel
Clowse, Megan E B
Eudy, Amanda M
Maharaj, Anil R
Hornik, Christoph P
Cohen-Wolkowiez, Michael
Gonzalez, Daniel
author_sort Balevic, Stephen J
collection PubMed
description OBJECTIVE: Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE. METHODS: We conducted a PK analysis using data from two observational pregnancy registries. We enrolled pregnant women with SLE taking HCQ at least 3 months prior to, and throughout pregnancy, and excluded those with multiple gestations. Using the PK model, we conducted dosing simulations and imputed 0%/20%/40%/60% non-adherence to evaluate the impact of adherence versus physiological changes on HCQ concentrations. We compared the effect of pregnancy-average non-adherent concentrations (≤100 ng/mL vs >100 ng/mL) on preterm birth using adjusted logistic regression. RESULTS: We enrolled 56 women who had 61 pregnancies. By the third trimester, mean apparent HCQ clearance increased by 59.6%. At a dosage of 400 mg/day, fully adherent patients are expected to have HCQ concentrations ≤100 ng/mL only 0.3% of the time, compared with 24.2% when 60% of doses are missed. Persistently low HCQ concentrations throughout pregnancy were associated with a significantly higher odds of preterm birth, controlling for lupus nephritis and race (OR 11.2; 95% CI 2.3 to 54.2; p=0.003). CONCLUSIONS: We observed significant changes in HCQ PK during pregnancy, resulting in a shortening in the drug’s half-life by 10 days; however, medication non-adherence had a more pronounced effect on HCQ exposure compared with physiological changes alone. Moreover, pregnant women with non-adherent HCQ concentrations had significantly higher rates of preterm birth. Accordingly, optimising adherence in pregnancy may be more clinically meaningful than adjusting HCQ dosage to account for physiological changes. PK modelling indicates that serum HCQ concentrations ≤100 ng/mL are suggestive of non-adherence regardless of trimester and may help identify pregnancies at risk for poor outcomes.
format Online
Article
Text
id pubmed-8744126
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87441262022-01-20 Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes Balevic, Stephen J Weiner, Daniel Clowse, Megan E B Eudy, Amanda M Maharaj, Anil R Hornik, Christoph P Cohen-Wolkowiez, Michael Gonzalez, Daniel Lupus Sci Med Reproductive health and APS OBJECTIVE: Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE. METHODS: We conducted a PK analysis using data from two observational pregnancy registries. We enrolled pregnant women with SLE taking HCQ at least 3 months prior to, and throughout pregnancy, and excluded those with multiple gestations. Using the PK model, we conducted dosing simulations and imputed 0%/20%/40%/60% non-adherence to evaluate the impact of adherence versus physiological changes on HCQ concentrations. We compared the effect of pregnancy-average non-adherent concentrations (≤100 ng/mL vs >100 ng/mL) on preterm birth using adjusted logistic regression. RESULTS: We enrolled 56 women who had 61 pregnancies. By the third trimester, mean apparent HCQ clearance increased by 59.6%. At a dosage of 400 mg/day, fully adherent patients are expected to have HCQ concentrations ≤100 ng/mL only 0.3% of the time, compared with 24.2% when 60% of doses are missed. Persistently low HCQ concentrations throughout pregnancy were associated with a significantly higher odds of preterm birth, controlling for lupus nephritis and race (OR 11.2; 95% CI 2.3 to 54.2; p=0.003). CONCLUSIONS: We observed significant changes in HCQ PK during pregnancy, resulting in a shortening in the drug’s half-life by 10 days; however, medication non-adherence had a more pronounced effect on HCQ exposure compared with physiological changes alone. Moreover, pregnant women with non-adherent HCQ concentrations had significantly higher rates of preterm birth. Accordingly, optimising adherence in pregnancy may be more clinically meaningful than adjusting HCQ dosage to account for physiological changes. PK modelling indicates that serum HCQ concentrations ≤100 ng/mL are suggestive of non-adherence regardless of trimester and may help identify pregnancies at risk for poor outcomes. BMJ Publishing Group 2022-01-07 /pmc/articles/PMC8744126/ /pubmed/34996856 http://dx.doi.org/10.1136/lupus-2021-000602 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Reproductive health and APS
Balevic, Stephen J
Weiner, Daniel
Clowse, Megan E B
Eudy, Amanda M
Maharaj, Anil R
Hornik, Christoph P
Cohen-Wolkowiez, Michael
Gonzalez, Daniel
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title_full Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title_fullStr Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title_full_unstemmed Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title_short Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
title_sort hydroxychloroquine pk and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
topic Reproductive health and APS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744126/
https://www.ncbi.nlm.nih.gov/pubmed/34996856
http://dx.doi.org/10.1136/lupus-2021-000602
work_keys_str_mv AT balevicstephenj hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT weinerdaniel hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT clowsemeganeb hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT eudyamandam hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT maharajanilr hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT hornikchristophp hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT cohenwolkowiezmichael hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes
AT gonzalezdaniel hydroxychloroquinepkandexposureresponseinpregnancieswithlupustheimportanceofadherenceforneonataloutcomes